AdjuTec Pharma AS

India Accepts Adjutec Patent Application for APC148

Oslo, Norway, June 6th, 2022 – AdjuTec Pharma, a privately held company developing novel antibiotic resistance breakers, is excited to announce that Indian authorities have granted our APC148 patent application. India has the highest incidence of patients infected by metallo-β-lactamase (MBL) producing bacteria. These enzymes are able to destroy nearly all antibiotics available on the market. The most serious MBL is called New-Delhi-Mutant (NDM) and was first described in India. NDM-producing bacteria are often associated with lung infections and are now spreading throughout the world. A recent NDM out-break in Portugal during the pandemic clearly emphasized the importance of developing products such as meropenem+APC148, to treat infections caused by NDM-producing pathogens (Mendez et al 2022, Microorganisms).

Bjørn Klem, AdjuTec Pharma CEO, comments “The patent in India is very important for Adjutec as it covers a large territory that has the highest incidence of MBL-producing pathogens. Together with APC148 patents previously approved in US, Europe and China, Adjutec patents now cover the most important global markets.”

About antimicrobial resistance (AMR) –

AMR is a global health and development threat. It requires urgent multi-sectoral action in order to achieve the Sustainable Development Goals (SDGs). WHO has declared that AMR is one of the top 10 global public health threats facing humanity. Misuse of antimicrobials are the main drivers in the development of drug-resistant pathogens. Lack of clean water and sanitation and inadequate infection prevention and control promotes the spread of microbes, some of which can be resistant to antimicrobial treatment. The cost of AMR to the economy is significant. In addition to death and disability, prolonged illness results in longer hospital stays at intensive care units and isolate wards. In addition, there is a need for more expensive medicines and financial challenges for those impacted. Without effective antimicrobials, the success of modern medicine in treating and preventing infections during major surgery and cancer chemotherapy, can be jeopardized.

About AdjuTec Pharma

AdjuTec Pharma is a Company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The Company technology offers a unique mechanism of action that inactivates bacterial defense enzymes and restores bacterial sensitivity to antibiotics. The Company lead product is APC148, a selective zinc chelator targeting bacteria metallo-ß-lactamase (MBL) enzymes. The technology is developed by Professor Pål Rongved and his group at Department of Pharmacy, University of Oslo. The Company is located at Oslo Cancer Cluster Innovation Park next to the Radium Hospital, Oslo.

For more information, please visit
Please contact: